May 9th 2024
As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
ISPOR Panelists Weigh the Success of APMs
May 19th 2020The alternative payment model (APM) doesn’t perfectly balance the competing interests of revenue growth and value-based care, but it has been a learning tool, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Teva, Celltrion Maintain Slender Discount to Rituxan
May 4th 2020Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.
Pfizer Says Biosimilar Competition Cuts Both Ways
April 30th 2020Pfizer is battling biosimilar competition as its brands lose exclusivity but it is fighting fire with fire, launching multiple biosimilars of its own. Biogen has extended its commercialization agreements for biosimilars and said its earnings picture improved in the first quarter of 2020.
Cheryl Larson Discusses Employer Initiatives to Battle Costs of Care
April 25th 2020Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, discusses the sticker shock of rising specialty drug costs and how biosimilars are going to be incorporated into efforts to push back against this medical inflation.
Employers Are in Good Position to Promote Biosimilars
April 7th 2020Because they will see greater savings, employers have greater incentive to embrace biosimilars than plan sponsors in the overall insured population. Employers can be advocates for policy changes that promote biosimilars by contacting legislators; they can organize email campaigns to reach lawmakers more easily.
Pharmacy Benefit Management Institute Acquired by MJH Life Sciences
April 3rd 2020MJH Life Sciences™, owner of The Center for Biosimilars®, has acquired the Pharmacy Benefit Management Institute (PBMI), the nation’s leading provider of research and education that informs, advises, and influences the industry on drug cost management.